Severe forms of neurocysticercosis: Treatment with albeimdazole
Carregando...
Fontes externas
Fontes externas
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
FapUNIFESP (SciELO)
Tipo
Artigo
Direito de acesso
Acesso aberto

Fontes externas
Fontes externas
Resumo
Study of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days. Dextrochloropheniramine and ketoprofen were the adjuvant drugs Multiple symptoms were observed in 90 9% of patients. Intracranial hypertension was manifested in 90.9%. Hydrocephaly occurred in 86.4%. Evolution was satisfactory in 10 patients, 8 died and 4 had sequelae. Tomographic studies showed the appearance of an isolated IVth ventricle in 9 patients, after ventriculoperitoneal shunt, before ABZ treatment in 3 of them, during in 5 and after treatment in one. Median clinical follow-up duration was 10 months for the patients who died and 3-4 years for survivors. In 3 patients there was an increase in cyst size during the administration of the 15 mg/kg/day ABZ dose, which was not observed in any patient when the 30 mg/kg/day dose was used.
Descrição
Palavras-chave
Albendazole Cysticercosis Dextrochloropheniramine Ketoprofen Neurocysticercosis Severe forms Treatment acetazolamide albendazole dexchlorpheniramine ketoprofen mannitol adolescent adult clinical article drug efficacy female human male neurocysticercosis Adolescent Adult Anthelmintics Brain Diseases Chlorpheniramine Female Follow-Up Studies Humans Male Middle Aged Prognosis Tomography, X-Ray Computed
Idioma
Inglês
Citação
Arquivos de Neuro-Psiquiatria, v. 54, n. 1, p. 82-93, 1996.








